In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for ...

Real-world data from Australian patients show that upadacitinib demonstrates strong efficacy in treating atopic dermatitis, ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD) ...

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their ...

The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings from a win ratio analysis ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...